Annovis Bio, Inc. (ANVS) News
Follow Annovis Bio, Inc. (ANVS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Annovis Bio, Inc. (ANVS) Partners With Weave Bio to Prep Buntanetap NDA
Annovis Bio will use Weave Bio’s AI platform to draft and manage the planned NDA for buntanetap, aiming to file soon after a 6—month Phase 3 AD topline readout expected in Mar 2027.Material DetailsContext by AI AnalystTh
NEWS | Sep 23, 2026, 12:03 PM UTC
L
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. NYSE:ANVS (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neuro
NEWS | Sep 23, 2026, 12:03 PM UTC
L
ANVS - Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
ANVS - Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
NEWS | Sep 23, 2026, 12:00 PM UTC
M
ANVS phase III Alzheimer’s trial enrolled; top-line due March
ANVS says its phase III Alzheimer’s trial is fully enrolled, with top-line data expected in March and an NDA filing to follow. It also plans a $15 million raise before Q4 to fund needs.
EQUITY | Sep 02, 2026, 09:39 PM UTC
L
Roth Capital cuts Annovis Bio price target to $7
Roth Capital cut its price target on Annovis Bio to $7.00/share from $8.00.
EQUITY | Aug 28, 2026, 05:27 PM UTC
L
ANVS - Annovis to Host Corporate Update Webinar on September 2, 2026
ANVS - Annovis to Host Corporate Update Webinar on September 2, 2026
EQUITY | Aug 25, 2026, 12:02 PM UTC
L
Annovis (ANVS) reports second-quarter 2026 results and corporate updates
Annovis (ANVS) issues corporate updates alongside its second-quarter 2026 financial results, according to the provided headline text.
EARNINGS | Aug 14, 2026, 12:00 PM UTC
H
Annovis Bio Announces Full Enrollment Of Its Phase 3 Trial Of Buntanetap In Patients With Early Alzheimer’s Disease; The Trial Enrolled 850
Annovis Bio, Inc. (NYSE: ANVS ) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s dis
EARNINGS | Jul 07, 2026, 11:19 AM UTC